12.99
0.36 (2.85%)
| Penutupan Terdahulu | 12.63 |
| Buka | 12.62 |
| Jumlah Dagangan | 202,862 |
| Purata Dagangan (3B) | 220,329 |
| Modal Pasaran | 474,517,536 |
| Harga / Jualan (P/S) | 11.15 |
| Harga / Buku (P/B) | 1.74 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2025 |
| EPS Cair (TTM) | -2.49 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.25% |
| Nisbah Semasa (MRQ) | 21.47 |
| Aliran Tunai Operasi (OCF TTM) | -39.28 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -26.34 M |
| Pulangan Atas Aset (ROA TTM) | -22.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Contineum Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.13 |
|
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 1.82% |
| % Dimiliki oleh Institusi | 79.99% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 20.00 (Baird, 53.97%) | Beli |
| Median | 17.00 (30.87%) | |
| Rendah | 14.00 (Morgan Stanley, 7.78%) | Pegang |
| Purata | 17.00 (30.87%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 11.53 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Baird | 06 Mar 2026 | 20.00 (53.96%) | Beli | 13.88 |
| Morgan Stanley | 08 Jan 2026 | 14.00 (7.78%) | Pegang | 9.17 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 28 Jan 2026 | Pengumuman | Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |